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Chronic obstructive pulmonary disease (COPD) is defined
by the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) as a disease state characterized by airflow limi-
tationthat isnotfully reversible (1). Cigarette smokingis the
most important risk factor for the development of COPD.
Although the dose-response relationship between cigarette
smoking and pulmonary function is well-established, there
is considerable variability in the reduction in FEV1 among
smokers with similar smoking exposures (2, 3). The low
percentage of variance in pulmonary function explained by
smoking suggests that there could be genetic differences in
susceptibility to the effects of cigarette smoking (4, 5). In ad-
dition to genetic factors, other environmental determinants
such as indoor biomass smoke exposure can be important
risk factors for COPD (6). A small percentage of COPD pa-
tients (estimated at 1–2%) inherit severe alpha-1 antitrypsin
(AAT) deficiency, which proves that genetic factors can in-
fluence COPD susceptibility. The discovery of AAT defi-
ciencywasamajorfactorinthedevelopmentoftheProtease-
Antiprotease Hypothesis for COPD, which has been one of
the prevailing models of disease pathogenesis for more than
40 years.
WiththesubstantialimpactofAATdeficiencyonourun-
derstanding of COPD pathogenesis, it was natural to hope
that the identification of other COPD susceptibility genes
w o u l dl e a dt os i m i l a rn o v e li n s i g h t si n t oC O P D .U n t i lr e -
cently, however, progress in the identification of additional
genetic risk factors for COPD has been slow.
To facilitate the development of such research, a meeting
of COPD genetics investigators was held on July 13–14, 2010
in Boston. The goals of the meeting were:
(1) To review the current state of COPD genetics research;
(2) To discuss existing study populations for COPD genetics
research throughout the world;
(3) Toconsideropportunitiesforcollaborationsbetweendif-
ferent COPD research groups through an International
COPD Genetics Consortium;
(4) To recognize challenges in building COPD genetics col-
laborations and to discuss them openly; and,
(5) To develop a framework for future collaborative studies.
CurrentstatusofCOPDgeneticsresearch
M a n yc a n d i d a t eg e n ea s s o c i a t i o ns t u d i e sh a v eb e e np e r -
formed over the past 40 years, but the results have been
largely inconsistent. These inconsistencies likely relate to
a variety of methodological issues, including small sample
sizes, variable definitions of case and control groups, fail-
u r et oa d j u s tf o rm u l t i p l es t a t i s t i c a lt e s t i n g ,a n di n a d e q u a t e
adjustments for population stratification and smoking expo-
sure. Most of the studies describing COPD-associated poly-
morphisms were performed in White populations (7). A
meta-analysisof20polymorphismsin12candidategenesin-
v o l v e di nt h ep r o t e a s e – a n t i p r o t e a s eb a l a n c ea n ds e v e r a la n -
tioxidant pathways showed that, after combining indepen-
dent studies, many of these candidate genes had no associ-
ation with COPD (8).
Anotherfactorlikelyimpedingtheprogressofidentifying
COPD susceptibility genes is the lack of accurate phenotypic
characterization of this complex and heterogeneous disease.
Airflow limitation determined by spirometry has been the
most common approach to classify and monitor the disease.
Structural changes of the lung including emphysema and
small airway obstruction are the primary processes that af-
fectlungfunction(9),buttheyarenoteasilydiscernablewith
t h es i m p l es p i r o m e t r i cm e a s u r e sc o m m o n l yu s e df o rp h e -
notyping COPD. Recent advances in characterizing patho-
logic changes such as emphysema and remodeling of the
smallandlargeairwaysbyquantitativeanalysesofimagedata
from multidetector computed tomography (CT), together
with physiological testing, have been helpful to differenti-
ate COPD phenotypes (emphysema-predominant, airway-
predominant, or mixed)(10). Study populations that have
chest CT data may help to better identify COPD-associated
genetic variations (11). Other potentially relevant COPD
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phenotypes, such as cachexia and low exercise capacity, have
not been widely analyzed in COPD genetic studies.
Perhaps the greatest problem in the candidate gene era
of COPD genetic studies was improper candidate gene se-
lection, which reflects our limited understanding of COPD
pathogenesis. However, the application of genome-wide as-
sociation studies (GWAS), which provide an unbiased and
comprehensive search throughout the genome for common
susceptibility loci, has changed the landscape of COPD ge-
netics. Based on GWAS, three genetic loci have been un-
equivocally associated with COPD susceptibility, located on
chromosome4neartheHHIPgene,onchromosome4inthe
FAM13A gene, and on chromosome 15 in a block of genes
which contains several components of the nicotinic acetyl-
c h o l i n er e c e p t o ra sw e l la st h eIREB2 gene.
In 2009, a series of studies provided convincing support
for these three genetic loci in COPD susceptibility. Pillai and
colleaguesfoundgenome-widesignificantassociationsofthe
CHRNA3/CHRNA5/IREB2 region to COPD (12). DeMeo
and colleagues performed gene expression studies of normal
vs. COPD lung tissues followed by genetic association anal-
ysis of COPD (13), suggesting that at least one of the key
COPD genetic determinants in the chromosome 15 GWAS
region was IREB2.
In the Framingham Heart Study (14), the HHIP region
was associated with FEV1/FVC at genome-wide significance
with replication of the effect on FEV1/FVC demonstrated in
an independent sample drawn from the Family Heart Study,
and this same region nearly reached genome-wide signifi-
cance with COPD susceptibility in the Pillai paper (12). Re-
c e n t l y ,t w op a p e r sp u b l i s h e di nN a t u r eG e n e t i c sf r o ml a r g e
generalpopulationsampleshaveprovidedstrongsupportfor
the association of HHIP SNPs with FEV1/FVC (15, 16). One
of these articles, from the CHARGE Consortium, also found
evidence for association of FEV1/FVC with the FAM13A lo-
cus(15),whichhasbeenstronglyassocia tedwithCOPDsus-
ceptibility (17).
Moreover, several case-control studies from other Eu-
ropean populations have replicated these findings by con-
firming significant associations to the chromosome 15q25
locus (CHRNA3/CHRNA5/IREB2) (18, 19), chromosome
4q31 locus (HHIP) (20, 21), and chromosome 4q22 locus
(FAM13A) (22). Thus, the frustration of inconsistent genetic
association results in COPD from the beginning of the last
decade has been replaced by optimism regarding the likely
importance of the IREB2/CHRNA3/CHRNA5, HHIP,a n d
FAM13A loci in COPD susceptibility.
Advantagesofcreatinglargenetworksforgeneticanalysis
There are likely multiple additional COPD susceptibility ge-
netic determinants that have not yet been identified. In
many other complex diseases, the creation of large col-
laborative consortia has enabled highly powered genome-
wide association studies that have led to the identification
of multiple novel genetic susceptibility loci. For example,
a Type 2 Diabetes mellitus consortium performed GWAS
in 8,130 Cases and 38,987 Controls and identified multi-
ple novel susceptibility loci (23). The International Lung
Cancer Consortium found new SNPs that were associated
with disease in Asian populations (24, 25). The ENGAGE
consortium discovered sequence variants associated with
smoking behavior within regions harboring nAChR genes
(CHRNB3–CHRNA6, 8p11) and a nicotine-metabolizing
e n z y m e( 2 6 ) .W ea n t i c i p a t et h a tas i m i l a rc o l l a b o r a t i v ec o n -
sortium approach in COPD could lead to the identification
of additional novel COPD genetic determinants.
Gapsincurrentgeneticknowledge
ThemostfundamentalgapincurrentCOPDgeneticsknowl-
edge is that there are probably many genetic determinants of
COPD, but only three genomic regions likely to contain such
susceptibility loci have been conclusively identified. More-
over, the functional genetic variants within the three existing
CO P DG W A Sr e gio n sr e m a int obef o un d .T oa d eq ua t e l ya n-
alyzethevarioussubtypesofCOPD,studiesthatincludemul-
t i p l ee t h n i cg r o u p sa sw e l la sm u l t i p l ee n v i r o n m e n t a lf a c t o r s
that influence inflammation will be required in large sam-
ple sizes. More recently, some studies have combined results
from several populations to increase the numbers of cases
and controls.In morethan 8300 subjects in seven study pop-
ulations,theminoralleleofaSNPinMMP12 was associated
with a positive effect on lung function and a reduced risk of
COPD (27). The genome-wide association study that identi-
fied FAM13A included three sets of COPD cases and smok-
ing controls (17). However, these studies are still underpow-
ered to identify genetic determinants of small effect, and es-
tablishingaconsortiumofgroupsstudyingcigarettesmokers
may facilitate pooling large samples to identify genetic vari-
ants associated with COPD susceptibility.
GENETIC TECHNOLOGIES AVAILABLE FOR AN
INTERNATIONAL COPD GENETICS CONSORTIUM
It is desirable that the full power of modern genetic and
genomic technology and techniques be brought to bear
on COPD. Statistical genetic approaches should begin with
meta-analyses of currently completed GWA studies, includ-
ing imputation of polymorphisms from the 1000 Genomes
Project. Analyses should routinely include epidemiologically
important covariates such as sex, age at onset, and smok-
ing history. Ancestry needs to be matched carefully between
cases and controls, using, for example, principal component
analyses. Multi-marker techniques to identify polygenic ef-
fectsbelowtheGWASthresholdmaybeusefulinidentifying
genes and pathways impacting on the disease.
Genome-wide SNP genotyping of several thousand or
more cases is necessary, particularly using existing European
panelsofsubjectsthathavenotyetbeengenotypedandcases
and controls of non-European ancestry. It is noted that there
exists a wide range of previously genotyped European con-
trols that could be used wherever possible.
Further meta-analysis of the full dataset should be com-
pleted after the additional genotyping. Ideally these re-
sults would be integrated with large-scale studies of other
smoking-related diseases (particularly lung cancer and car-
d i o v a s c u l a rd i s e a s e ) ,w i t hs t u d i e so fs m o k i n gb e h a v i o ra n d
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addiction, and studies of diseases characterized by compro-
mised lung function (in particular, asthma).
F i n em a p p i n go fs e l e c t e dl o c it oi d e n t i f yf u n c t i o n a lv a r i -
antswillbenecessary.Thiswillincludestatisticalapproaches
such as multiple regression as well as additional genotyp-
ing. The particular importance of including ancestral groups
of non-European origin in these analyses is noted, in order
to use their differences in linkage disequilibrium patterns to
break up linkage disequilibrium blocks, and to demonstrate
generalizabilityofvariantsassociatedwithCOPDtothepop-
ulation at large.
Next-generation DNA sequencing approaches have the
capacity to discover highly penetrant rare variants in com-
mon diseases such as COPD. Limiting sequencing to the ex-
o m eg r e a t l yr e d u c e sc o s t sc o m p a r e dt ow h o l eg e n o m es e -
quencing approaches, while retaining much of the informa-
tion that is likely to lead to the identification of disease-
related rare variants. Although the value of exome sequenc-
ing has not yet been established in complex genetic diseases,
it is desirable to explore the use of exome sequencing to
search for rare mutations in patients with severe spectrum
disease, including non-smokers with COPD as a separate
group.
Genomic studies allow systematic investigation of path-
waysandnetworksofgenefunctionsunderlyingdisease(28).
Investigations for COPD should include mapping of expres-
sionquantitativetraitloci(eQTL)andnetworkidentification
frommeasurementsofglobalgeneexpressioninairwaybiop-
sies and peripheral blood DNA samples. It would also be im-
portant to carry out eQTL mapping and network identifica-
tion with global gene expression in current cigarette smok-
ersandnon-smokers.TheinvestigationofmethylQTL(using
genome-wide methylation arrays) should similarly be imple-
mented in order to explore epigenetic effects on COPD and
related phenotypes.
Lastly, it is now possible to quantify bacterial coloniza-
tion of airways using DNA and RNA sequencing techniques
that address the hyper-variable bacterial 16S gene as well as
metagenomic approaches that examine the global gene con-
tent and gene expression of human bacteria (29). It is there-
forerecommendedthatsystematicstudiesofthemicrobiome
be carried out in patients with COPD. These studies should
include 16S sequencing for bacterial identification; metage-
nomicsequencingandmeasuresofbacterialgeneexpression;
and investigation of relationships of these measures to host
gene expression and genotype.
COPD PHENOTYPING AND KNOWLEDGE GAPS
Clinicalphenotypes
Precise definition and validation of clinical phenotypes are
key prerequisites to identify the genetic basis of complex dis-
eases, since a principal goal of genetic research is to iden-
tify specific genotypes that link to specific phenotypes (30,
31). From the genetics point of view, if current approaches
in defining phenotypes are inadequate, the huge amount
of currently available genotypic data cannot be optimally
used (32). A recent consensus definition (11) proposes that
a “COPD clinical phenotype” is “a single or combination of
d i s e a s ea t t r i b u t e st h a td e s c r i b ed i f f e r e n c e sb e t w e e ni n d i v i d -
uals with COPD as they relate to clinically meaningful out-
comes(sym ptoms,exacerba tions,responsetothera py ,ra teof
disease progression or death).” Thus, for a COPD phenotype
to be of use in a COPD genetics study, it has to be associated
with clinically meaningful outcomes. Some inconsistent re-
s u l t sp u b l i s h e ds of a ro nt h eg e n e t i cb a s i so fC O P Dm a yb e




The degree of airflow limitation remains the defining
characteristic of COPD and thus its most important pheno-
typicexpression.However,thereissufficientevidencetosup-
port the need to consider additional phenotypic expressions
inthecharacterizationofpatientswithCOPD.Theseinclude:
1)thedegree,typeanddistributionofemphysema(discussed
below); 2) the extent of airway wall thickening caused by in-
flammation; 3) the degree of hyperinflation expressed by the
ICandtheIC/TLC;4)thepresenceofabnormalgasexchange
( h y p o x i aa n dh y p e r c a p n i a ) ;5 )t h ep r e s e n c eo fs y s t e m i ci n -
volvement as measured by the BMI; 6) the exercise capacity
whethermeasuredinthelaboratory(peakoxygenuptake)or
in the field (6-minute walk test); and 7) the degree of func-
tional dyspnea. These characteristics can practically be in-
tegrated into multidimensional tools such as the BODE in-
dexcapableofprovidingamorecomprehensiveevaluationof
COPD subjects (34). The determination of these phenotypic
characteristics is not only scientifically interesting, but also
clinicallyimportantbecausetheyconferprognosticvalueand
more importantly, they determine response to therapy. Al-
though COPD genetic studies have focused primarily on the
presence/absence of COPD, analysis of these additional phe-
notypescouldprovideusefulinsightsintoCOPDpathophys-
iology.
The study of COPD phenotypes is relevant to disease eti-
ology, pathophysiology, and treatment. The identification of
clinicallyrelevantphenotypeswouldchangethepresentview
of COPD as a unique multicomponent disease (35, 36) to a
syndromewithmultiplephenotypicexpressions,thuschang-
ing (and challenging) current taxonomy of chronic airway
diseases (37). Regarding disease etiology, the identification
ofnon-geneticdeterminantsofdiseaseswillalsobenefitfrom
an appropriate definition of phenotypes. It is also likely that
the traditional approach to address heterogeneity (i.e., strat-
ification by socio-demographic, clinical, or environmental
factors) is likely to lead to a reduction in statistical power
(30). On the other hand, the identification of clinically rele-
vantphenotypesshouldalsoleadtoincreasedunderstanding
of the underlying pathobiology that contributes to a partic-
ular phenotype (31). Despite the huge advances in our un-
derstanding of the pathology of COPD in recent decades,
there have been few attempts to link COPD pathologies to
clinical COPD phenotypes (38). Finally, it has been hypoth-
esized that failure to identify COPD phenotypes may limit
the power of therapeutic trials (39) as effective and safe ther-
a p yi sl i k e l yt od i f f e ra c r o s sp h e n o t y p e s( 3 1 ,4 0 ) .S e v e r a l
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already existing examples illustrate this point, including the
useoflong-termoxygentherapyforCOPDwithchronicres-
piratory failure (but not for those with PaO2 values above 60
mmHg) (41, 42), the use of lung volume reduction surgery
for patients with upper-lobe predominant emphysema and
poor exercise capacity after rehabilitation(43), and, more re-
cently, the development of roflumilast (a novel orally avail-
able anti-inflammatory drug) for only a subgroup of patients
with COPD (those with chronic bronchitis) (44). Large, on-
g o i n gC O P Ds t u d i e sm a yp r o v i d ei n s i g h ti n t op h e n o t y p i n g
based on larger populations with more detailed descriptors.
ChestCTphenotypes
The use of chest CT scans for determination of lung density
was first described in the 1980s as a measure of the degree
of emphysema in COPD (45). An important step was the in-
troduction of digital image analysis software, such that the
density of the entire lung can now be reported as the lower
1 5 t hp e r c e n t i l ei nH o u n s f i e l du n i t so rt h ep e r c e n t a g eo fl u n g
below a specific density mask threshold (e.g., < −950 HU)
to define emphysema.
A more recent approach is the assessment of the thickness
oftheairwaywallsinordertodeterminethedegreeofairway
remodelling. This was initially applied to asthma and more
recently also to COPD (46). This approach appears to be ro-
bust for larger airways, and percent airway wall area can be
used as a read-out (47). Although large airway dimensions
correlate with small airway dimensions (48), direct assess-
ment of the latter (airways <2 mm in diameter) is beyond
the resolution of current CT scanning techniques. Quantita-
tive assessment of chest CT scans for emphysema and airway
disease provides an opportunity to define these two key phe-
notypesofCOPDbyobjectivecriteria.Theremayalsobefur-
therrelevantCT-definedphenotypesthatneedmoredetailed
study as to their clinical relevance and this includes emphy-
sema distribution, emphysema pathological subtype (cen-
trilobularvs.panlobularvs.paraseptal),thedegreeofmucus-
mediated obstruction (plugging of airways), and bronchiec-
tasis.
An important issue for multicenter trials is standardiza-
tion of CT measurements across different clinical centers.
Here the different brands and models of CT scanners, which
use different scanning technologies, scanning protocols, and
different algorithms for data processing, can affect the lung
density and the airway wall results. Careful standardization
including the use of phantoms for all scanners is required in
ordertobeabletocompareresults.Inspiteoftheseproblems,
i tm a ybepo s s i b l et oo b ta i nd a tao nC T - a s se s sede m p h y se m a
which could be compared in a multicenter study.
EXISTING COPD STUDY POPULATIONS
A tt h eBo s t o nm e e t i n g ,3 8s t u d ypo p u l a t i o n sw h i c hi n c l u d e d
spirometric assessment of COPD and DNA sample collec-
tion were reviewed (Table 1). These studies included 20 case-
control studies (or studies of cases only or controls only,
which will all be included as “case-control” for this discus-
sion), 16 population-based cohort studies (some of which
had family components), and two family-based studies. De-




in White populations. Most of the case-control studies in-
clude post-bronchodilatorspirometry and a minimum num-
ber of pack-years of smoking criterion for inclusion, while
mostofthepopulation-basedcohortstudiesdonot(Table2).




Using the reported definitions of COPD and non-COPD
fromeachstudy,thereareapproximately39,600COPDcases
and 131,600 control subjects in the combined set of case-
control and population cohort studies (Table 3). In these
case-controlandpopulationcohortstudies,thereareapprox-
imately 14,700 cases and 37,600 controls reported to have
genome-wide SNP genotyping currently available.
WORKSHOP RECOMMENDATIONS FOR CREATION OF
AN INTERNATIONAL COPD GENETICS CONSORTIUM
Rationaleandvision
At the Boston meeting, the participants identified multiple
advantages of creating a COPD genetics research consor-
tium, and strongly endorsed this approach. Larger sample
sizes of cases and controls will definitely increase power to
detect COPD susceptibility loci. The potential to assemble
large numbers of severe COPD subjects that are clearly af-
fected is a major advantage, since relatively small numbers of
severely affected subjects have been included in most indi-
vidual studies. Similarly, the opportunity to perform pooled
analysesofchestCTphenotypeswasseenasamajorstrength,
as long as the technical challenges of different CT scanning
and analytical protocols can be overcome. Opportunities to
study other COPD-related phenotypes, including COPD ex-
acerbation frequency, lung function decline, and lung can-
cer,werealsorecognized.Althoughmanyoftheparticipating
studies do not yet have genome-wide SNP genotyping, these
studies provide opportunities to replicate initial GWAS find-
ings in large numbers of additional subjects. In addition to
studies of main genetic effects, a large COPD genetics con-
sortium would improve the statistical power to study gene-
by-environment interactions.
Although the studies listed above could be performed in
a fairly short time-frame, potential future advantages of a
COPD genetics consortium were also appreciated. Such a
consortium could provide a framework for future genetic
collaborations in exome sequencing and whole genome se-
quencing,aswellasinothergenetic/genomicareas(e.g., epi-
genetics, gene expression). There would likely be increased
standardization of study protocols and procedures for fu-
ture studies (e.g., imaging, questionnaires) and the poten-
tial for collaborative studies of non-genetic issues (e.g., phe-
notypes, biomarkers). Limitingduplication of research effort
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Table 3. International COPD Genetics Consortium: Approximate
current study population sample sizes
Cases Controls
Case-Control Studies (or Case-Only Studies) 23,039 15,610
Cohort Studies 16,526 115,956
Combined Set 39,565 131,566
GWAS in Combined Set Currently Available 14,741 37,612
N o t e s :F o rt h i st a b l e ,a p p r o x i m a t es a m p l es i z e sf r o mT a b l e1w e r eu s e da sa c t u a l
values. Only subjects with spirometry from Table 1 were included in these calcu-
lations (MESA Lung SHARe was excluded). Population-based studies with a fam-
ily component (e.g., Framingham) are listed under “Cohort Studies,” while other
pedigree-based studies (e.g. International COPD Genetics Network) have been ex-
cluded. For the “GWAS in Combined Set Currently Available,” only subjects with
available genotyping by December 2010 were included.




In addition to these advantages of forming a collaborative
consortium,avarietyofchallengeswereidentified.Itwasrec-
o g n i z e dt h a tt h e r ea r ea c a d e m i cr e a l i t i e si n c l u d i n gt h en e e d
forindividualresearchgroupsto demonstrateacademic pro-
d u c t i v i t yt or e n e wf u n d i n ga n dp r o m o t er e s e a r c hp e r s o n -
nel. Some COPD genetics collaborations already exist, and
a goal was not to interfere with those existing relationships.
Although studies that include reasonable numbers of COPD
casesandcontrolsubjectscouldbeanalyzedindividuallyand
combined using meta-analytical approaches, the optimal ap-
proach for utilizing studies of COPD cases only or controls
only was not as clear.
A variety of challenges related to phenotypic characteri-
zation were also identified. Substantial variation exists in the
definitions of cases and controls between studies (e.g., phys-
i o l o g i cm e a s u r e m e n t so fl u n gf u n c t i o nu s i n gG O L Dc r i t e r i a
o ru seo fl o w e rl i m i to fn o rm al[ L L N ] ) ,a sw e lla si ns p i r o m e -
tryprotocol(e.g.,pre-vs.post-bronchodilator).Somepheno-
types(e.g.,imaging)maybedifficulttocombineacrossstud-
ies due to technical issues. There are important variations in
study populations (e.g., race/ethnicity, smoking history, ex-
cl usio no fsub jectswi tho therillnesses,o thercri teriausedfo r
selection, study design, and informed consent restrictions)
and genetic analysis approaches (e.g., variation in genotyp-
ing platform, data cleaning, analytical approaches, and data
sharing).
Despitethesechallenges,therewasgeneralagreementthat
the advantages of collaboration far outweighed the limita-
tions, and that a transparent and open collaboration could
overcome most of the challenges. To be successful, the needs
and rights of each contributing study will need to be re-
spected. Based on the enthusiastic support for an interna-
tional COPD genetics consortium from the Boston meeting
participants, the research projects amenable to this consor-
tium approach and an organizational structure for the con-
sortium were discussed.
FeasibilityofcollaborativeCOPDgeneticsstudies
Although the development of large consortia of thousands of
subjectsmayobviatesomeoftheissuesthathavecontributed
tonon-replicationofpreviousCOPDgeneticstudies(suchas
power limitations germane to smaller studies), the inclusion
of data from a large number of studies presents unique chal-
lenges and opportunities.
Smokingexposureandpenetrance
Despite the challenges of disease gene discovery in complex
disease, there are some striking advantages to studying the
genetics of COPD (COPD strictly being a syndrome not a
specific disease). First, one of the most important features of
studying the genetics of COPD is that the key environmental
exposure of cigarette smoking is known and quantifiable in




tal exposure (pack-years), across both cases and controls in
geographicallydiversepopulations.Thecentralroleofsmok-
ing exposure in genetic susceptibility is illustrated by the di-
vergent outcomes in people with alpha-1 antitrypsin defi-
c i e n c yb a s e do nt h e i rs m o k i n gh i s t o ry( 4 9 ) .
Second, although COPD is a syndrome encompassing
both emphysema and small airway disease that are present
in varying degrees, both are characterized by irreversible air-
flow limitation (reduced FEV1 and FEV1/FVC ratio), which
ca nbem eas ur edb ysim p les p ir o m etryinpo p ula tio ns t udies.
From an epidemiological perspective, FEV1 (after age, gen-
der, race, and height adjustment) provides a good starting
place from which to define COPD, as it is a highly herita-
ble trait (50) regardless of the heterogeneity of COPD sub-
jects.Moreover,withincreasingsmokingexposure,FEV1 de-
fines susceptible and resistant smokers with an increasingly
bimodal distribution supportive of a genetic basis (2, 51–53)
a n dp o s s i b l yat h r e s h o l de f f e c t .C o m p a r i n gs m o k e r sa te i -
therendoftheFEV1 spectrumbutwithcomparablesmoking
exposure, so called “extreme phenotypes” (54), may help to
overcome minor differences in spirometric criteria defining
the COPD phenotype.
Despite these characteristics of COPD as a complex ge-
netic disease, there remain significant challenges in combin-
ing population-based and case-control samples. Many stud-
ies that can be included in a collaborative COPD meta-
analysis have not taken detailed smoking histories or vali-
datedintensityofcurrentsmokingviameasurementsofcoti-
nine levels. Although reporting bias is a concern, self-report
of cigarette smoking has been demonstrated as a reliable as-
sessment.
Some of the studies proposed for inclusion in this consor-
tium have focused on a minimum amount of smoking expo-
sure for enrollment, while others have not. Similarly, some
st udiesha vef ocusedo nthehea vysmok er ,a ndso meha vein-
cluded a range of exposures. Including all studies allows for
a reasonable attempt to achieve the necessary power to as-
sess genetic main effects, but also gene-by-smoking interac-
tions through stratification and/or adjustment. In addition,
geneticinsightsintoCOPDwillbegleanedbynotonlystudy-
ing those genes that associate with COPD susceptibility, but
also genes that may portend protective resistance to COPD
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in subjects with an extremely high number of pack-years but
normal lung function.
HeterogeneityofCOPD
First and foremost in the planning and organization of large
consortia with the goal of meta-analysis, the heterogeneity
of phenotypes across studies needs to be addressed. This is
a ni s s u eb yn om e a n sl i m i t e dt or e s p i r a t o r yg e n e t i cs t u d -
ies. A paramount challenge in studies of COPD has been
the inherent heterogeneity of the disease, variable effects of
smokingexposureonpenetrance(describedpreviously),and
the importance of defining disease subtypes. In addition,
not all studies have performed pre- and post-bronchodilator
spirometry, and many studies have not been sufficiently re-
sourcedtoundertakechestCTscanningtophenotypeCOPD
p a t h o l o g i c a l l y .E v e ni nt h ep r e s e n c eo fp o s t - b r o n c h o d i l a t o r
spirometry, issues of spirometric diagnosis of COPD based
on using GOLD criteria versus lower limit of normal may
contribute to phenotypic heterogeneity. This is likely to be
minimizedinthosecase-controlstudiescomparingmoreex-
treme (susceptible vs resistant) phenotypes where misclassi-
ficationofcasesorcontrolsbasedonvariationinspirometry-
based definition is likely to be minor. However, severity of
COPD is an issue that needs careful consideration given the
strong association between aging and loss of lung function.
Moreover, it is noted that a spirometric diagnosis of a re-
sistant smoker does not obviate some misclassification as
smoking-related emphysema may be present despite normal
spirometric measures.
A major strength of this consortium will be the availabil-
i t yo fd a t af r o mb o t hs p i r o m e t r ya n dC Ts c a n so ft h el u n g s
for parsing subjects by emphysema status (and also within
COPD cases for emphysema versus airway predominant
disease). Although CT scanning presents challenges (lack
of uniformity of scanner technical characteristics, scanning
protocols, radiation dosing, scoring of emphysema sever-
ity/distribution, etc.), computerized approaches to process
and analyze chest CT scans may be useful in harmonizing
CT scan data, and will likely assist in refinement of COPD
subtypes.
Ethnicheterogeneity/populationsubstructure
Although the inclusionof data fromCaucasian, African, Na-
tive American, and Asian subjects may lead to false posi-
tive and/or false negative association findings due to popu-
lation substructure, contribution of all subjects’ data to the
power of the overall analysis, and to the race-specific genetic
association analyses of COPD, are major strengths of per-
forming a multi-ethnic consortium. There are many existing
examples of disease associations confined to specific ethnic
groups. Primary analyses would be conducted within each
ethnic group, followed by comparison of association results
between groups.
Study-speciﬁcissues
Although the inclusion of many studies of COPD may in-
c r e a s et h ep o w e rd u et oa ni n c r e a s ei nt o t a ls u b j e c tn u m -
ber, presently a minority of COPD studies have GWA data.
Given the large burden of disease accounted for by COPD,
this void of GWA data in and of itself supports the impor-
tance of efforts to accrue more GWA data. The consortium
will include GWA data on both population-based cohorts
and case-control studies. In the population-based cohorts,
the contribution of genetic variants on lung function can be
explored in settings other than chronic smoking.
ThereisaneedformoreGW Adataincase-controlstudies,
w h e r es m o k i n gh a sb e e na c c o u n t e df o ra n do t h e ri m p o r t a n t
exposureshavebeenexamined.Case-controlstudiescanalso
allow investigation of the role in disease of variants shown to
be associated with lung function in population-based stud-
ies. The case-only studies can be added to the case-control
studiesinamega-analysisofindividualgenotypeandpheno-
typedata,orincircumstanceswheredatacanbecombinedor




s t u d i e d ;t h i sc o u l db ei n s i g h t f u l ,f o re x a m p l e ,f o rt h o s ev a r i -
a n t ss h o w nt ob ea s s o c i a t e dw i t hC O P Do rc r o s s - s e c t i o n a l
lung function measures.
Other study-specific issues include variations in enroll-
ment criteria, age ranges of subjects, and rates of co-morbid
conditionsincludingobesitywhichmayaffectlungfunction.
Ofthese,variationsinsmokinghistory(describedabove)and
current smoking status are potentially the most essential, as
some of the COPD studies had minimum amounts of smok-
ingexposurerequiredforeligibility,andincludeamixofcur-
rent and former smokers. Given that gene-by-smoking inter-
actions are crucial to include in genetic analyses (2, 51–53)






re-examined with stratification by age of disease onset, to-
talpack-yearexposureandcurrentsmokingstatuswherethe
data are known.
Variable rates of comorbidities in the different COPD
studies may impact genetic associations with lung function
(suchastheassociationofdiabeteswithlowerlungfunction)
buttheinclusioningeneticanalysisofthemostdiversegroup
with COPD may increase the likelihood that positive associ-
a t i o n sa r et r u ep o s i t i v ef i n d i n g s .
GWASplatformsanddatacleaning
As has been the challenge in other complex diseases such
as diabetes, the platforms used for genome-wide genotyping
have varied. There is variable inclusion of SNPs leading to
differential coverage of genes on a given platform. However,
thisrealityhasledtotheavailabilityofimputationmethodsto
overcome the differences between GWA arrays; these novel
in silico tools allow for the development of a larger study
populationlessconstrainedbychoiceofgenotypingtechnol-
ogy. In addition to the genotyping platform, approaches to
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datacleaningmayvarybetweenbioinformaticsgroups.How-
ever, a harmonized approach to data cleaning is mandatory.
Sharingofindividualsubjectdata
The protection of human data and subject privacy is
paramount and the ability to share individual level geno-
typeresultsmaybelimited.Thus,theperformanceof“mega-
analysis” in which individual-level genotype and phenotype
data would be shared, though remaining a worthwhile even-
tual goal, was judged not to be essential to progress at this
time.However ,meta-analyticapproachesthatusestudy-wide
association data (p-values) weighted by study size or by in-
v e r s ev a r i a n c eh a v eb e e ns h o w nt ob ea sp o w e r f u la sm e g a -
analysis approaches that utilize subject level data (55). Thus
for identification of common variants for COPD (at least 5%
minor allele frequency) meta-analytic approaches will pro-
vide important insights into COPD.
Planforinitialmeta-analysis
A preliminary design for the initial collaborative genetic as-
sociationmeta-analysisfortheconsortiumwascreatedatthe
Boston meeting. Two key genome-wide association analy-
ses were proposed: 1) All COPD vs. Controls, and 2) Se-
vereCOPDvs.Controls.TheprecisedefinitionsofAllCOPD
and Severe COPD remain to be determined. Within each
study population that has existing genome-wide SNP geno-
typingdata,standardqualitycontrolapproacheswillbeused
tocleanthedata,includingcriteriaforexclusionofSNPswith
low call rates, low minor allele frequency, departures from
Hardy-Weinberg equilibrium, and differential rates of miss-
ing data between cases and controls, and exclusion of indi-
viduals with low call rates or exhibiting cryptic relatedness
among unrelated samples.
Standard approaches to genotype imputation will be ap-
plied in each study, followed by a similar approach to popu-
lation stratification adjustment within each study using ad-
justment with principal components for genetic ancestry.
Genome-wide association analysis for the two COPD affec-
tion status phenotypes (all COPD and severe COPD) will
be performed within each study, with separate analyses in
subjects of Caucasian, Asian, and African ancestry. Meta-
analysisofGWASwillbeperformedwithineachmajorracial
group using inverse variance weighted meta-analysis meth-
ods to account for differences in sample size and imputation
qualityacrossgenotypingplatforms,followedbycomparison
of association evidence between major racial groups. Finally,
replication genotyping and association analysis of the most
interesting SNPs will be performed in the remaining study
populations without genome-wide SNP data.
StructureoftheConsortium
The mandate of the International COPD Genetics Consor-
tium is to find common and rare genetic determinants of
COPD; to identify COPD subtypes and their genetic basis;
and to use this information to develop new disease classifi-
cations and therapeutic interventions. Based on the discus-
sions at the Boston meeting, it was recommended that re-
search studies including COPD and control subjects would
beinvitedtoparticipateiftheycollectedhighqualityspirom-




i n c l u d ec a s e - o n l yc o l l e c t i o n s ,t h e yw o u l db ee n c o u r a g e dt o
find appropriate sets of control subjects for genetic associa-
tion analysis; if not available, those COPD study populations
couldbeincludedinstudiesofCOPDprogressionorCTsub-
types. Study populations meeting these criteria that were not
represented at the Boston meeting will be welcome to join
this international collaborative effort.
Several committees will be created to perform the consor-
tiumresearchandadministration,includingaSteeringCom-
mittee (in charge of major decisions); Planning/Executive
Committee(routineoperations);PhenotypeHarmonization;
Imaging Committee; Genotyping and Genomics Core; and
Analysis Core.
The International COPD Genetics Consortium has the
potential to provide short-term results by providing highly






(1) Create the International COPD Genetics Consortium
(ICGC) – to be open worldwide to include all study pop-
ulations meeting minimum criteria for size, spirometric
data, and DNA availability.
(2) Mandate of the ICGC is to:
(a) U sepooledr eso ur cestodefinerar eandco mmo nge-
netic determinants of COPD
(b) Identify COPD subtypes and their genetic basis
(c) Develop new disease classifications for COPD
(d) Fosterdevelopmentofnewtherapeuticinterventions
that are subtype or disease classification specific
(3) Recommended committee structure:




(d) Phenotype Harmonization Committee
(e) Genotyping and Genomics Core
(f) Analysis Core
(4) Generating new GWAS/genotyping/sequencing/gene
expression data
(a) Expand and extend existing and ongoing genetic
analysis projects
(5) Plans for genetic analysis
(a) Initialmeta-analysisfocusedoncommondefinitions
of case status and on extreme phenotypes
(b) Commonstandardizedqualitycontrolapproachesto
clean data
(c) Standard approach for data analysis
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(a) Optimize data sharing while protecting privacy and
personal health information
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